trending Market Intelligence /marketintelligence/en/news-insights/trending/djNTfeAFY9KGEwRN2P-P2A2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Humana to cover NanoString's breast cancer testing kit

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Financial Industry Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021


Humana to cover NanoString's breast cancer testing kit

Humana Inc. decided to include NanoString Technologies Inc.'s Prosigna breast cancer gene signature assay in its coverage.

The insurer's decision is in accordance with the ASCO guidelines, which consider Prosigna to be medically necessary in assessing whether adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients is required, when adjuvant chemotherapy is not precluded due to any other factor.